Rheumatoid Arthritis: Risks and Benefits of Latest Treatments
This paper reviews the risks and benefits of current pharmacological treatments for rheumatoid arthritis (RA), a chronic inflammatory condition affecting approximately 1% of adults. Drawing on peer-reviewed literature, the paper examines methotrexate (MTX) as a cornerstone therapy, assessing its neurological, gastrointestinal, hepatic, and pulmonary side effects alongside its proven efficacy. The review then explores biological DMARDs, including tocilizumab and anti-TNF agents, discussing their mechanisms of action and associated risks such as serious infection and metabolic complications. The paper concludes with a call for further research and improved patient education tools to support informed treatment decisions.
- Introduction: RA overview and methotrexate as primary treatment
- Methotrexate: Efficacy and Safety Profile: MTX history, mechanisms, and proven effectiveness
- Side Effects of Methotrexate: Neurological, gastrointestinal, hepatic, and pulmonary risks
- Biologic DMARDs: Advances and Risks: Tocilizumab and anti-TNF biological therapy risks
- Infection Risk with Biological Therapies: Systematic review data on serious infection rates
- Future Research and Patient Education: Patient beliefs, education needs, and future study
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Organizes a complex pharmacological topic through a clear risk-benefit framework, making technical content accessible and logically structured.
- Synthesizes multiple peer-reviewed sources to build a cumulative argument, moving from established therapy (MTX) to newer biologics and finally to future directions.
- Balances clinical detail — including specific statistical findings such as OR values and infection rate increases — with accessible prose that contextualizes those figures for a general academic audience.
Key academic technique demonstrated
The paper demonstrates systematic literature synthesis: each source is introduced with its authors and date, its key findings are summarized, and those findings are connected to the paper's central risk-benefit argument. This technique shows how a literature review builds an evidence base rather than simply listing sources.
Structure breakdown
The paper opens with a brief introduction defining RA and establishing methotrexate as the central treatment. A literature review section follows, organized thematically around MTX side effects, the emergence of biologic DMARDs, and quantitative infection-risk data. A short concluding section addresses future research needs and patient education. The structure reflects a typical health-sciences literature review format.
Introduction
Rheumatoid arthritis (RA) is a form of arthritis characterized by swelling and tenderness; recent studies have revealed that approximately 1% of adults suffer from this condition. A common symptom is symmetric polyarticular inflammation of the synovium, typically affecting the small joints of the hands (MCP and PIP), wrists, and feet. This swelling causes discomfort and difficulty of movement and can result in gradual joint injury characterized by deformity and disability.
The major compound used in treating RA is methotrexate (MTX). This compound has been used for over 40 years in treating various types of rheumatic diseases and remains one of the most effective treatment methods for RA. Its combination with modern treatments that address disorders of the immune system — conditions treated by biological DMARDs — has transformed the approach to managing RA. This review provides a concise analysis of the risks and benefits of various therapies for rheumatic diseases, with emphasis on rheumatoid arthritis.
Methotrexate: Efficacy and Safety Profile
Bird and Littlejohn (2014) found that the earliest documented application of methotrexate was largely unnoticed, yet that moment marked the beginning of MTX's journey to becoming a widely accepted modern medication for rheumatic diseases. This journey from obscurity to prominence took the better part of thirty years; however, MTX eventually became a standard treatment for rheumatic conditions. The exact mechanism by which MTX treats rheumatic diseases remains incompletely understood. The most widely held belief is that MTX inhibits de novo pyrimidine and purine synthesis, thereby halting lymphocyte proliferation. Other proposed mechanisms include increased apoptosis of T cells, modification of the expression of cellular adhesion molecules, a surge in the release of the endogenous anti-inflammatory compound adenosine, and anti-angiogenesis effects via indirect mechanisms such as disruption of macrophage interaction (Bird & Littlejohn, 2014).
The effectiveness of MTX in treating RA is well established. In addition to reducing the signs and symptoms of RA, it slows the progression of joint damage, improves quality of life, and reduces mortality rates. Notably, combining MTX therapy with anti-TNF agents has been shown to produce greater positive effects than applying anti-TNF agents alone. This finding reinforces the view that, despite new technologies developed to treat RA, MTX remains an important treatment for a large number of patients (Bird & Littlejohn, 2014).
Several concerns have been identified regarding the safety of MTX use in treating rheumatic disease. These concerns are addressed below using a risk-benefit framework.
Side Effects of Methotrexate
Psychological side effects of MTX include fatigue, headaches, and reduced alertness. These adverse effects may limit treatment escalation but can be mitigated by supplementation with folic acid (Bird & Littlejohn, 2014).
The most common gastrointestinal side effects include mucositis, mouth ulceration, nausea, and diarrhea. These do not occur frequently because they are largely prevented by proper use of folic acid supplements and can be resolved by reducing or discontinuing the medication (Bird & Littlejohn, 2014).
Weekly administration of low doses of MTX can have adverse effects on the liver; reversible transaminase elevation, liver fibrosis, and liver cirrhosis are the most commonly reported. In practice, however, reversible transaminase elevation is the most frequently recorded outcome, while fibrosis and cirrhosis are rarely seen — largely because their known precursors, such as excessive alcohol intake or pre-existing liver disease, can be identified in advance. Patients on low-dose MTX are routinely monitored for transaminase levels, and decisions to reduce or discontinue the drug are made based on the degree of elevation (Bird & Littlejohn, 2014).
A very rare side effect — occurring in approximately 0.08% of treated patients — is lung disease, which may occur in patients on MTX treatment alone or in combination with other medications. Additional factors that increase susceptibility to MTX-induced lung damage include pre-existing interstitial lung disease (ILD), cigarette smoking, and low body weight (Bird & Littlejohn, 2014).
Small weekly doses of MTX provide effective, low-cost, and widely accepted treatment for RA. Medical personnel, however, must be well versed in the risks associated with its administration and remain vigilant in monitoring for them (Bird & Littlejohn, 2014).
Always verify citation format against your institution’s current style guide requirements.